Baebies has delivered 10 million tests to newborn screening labs around the world since the company was founded. This milestone translates to 10 million chances to provide a healthy start. Learn more about Baebies mission and growth.
According to the CDC, the “gold standard” for SARS-CoV-2 testing is reverse transcription polymerase chain reaction (or RT-PCR). Digital microfluidics enables ultra-rapid PCR results by utilizing low droplet volume with built-in heaters and sensors on cartridge.
While the COVID-19 pandemic has brought unprecedented challenges to public health, newborn screening (NBS) found a way to not only continue but expand over the past year. State NBS programs have continued to implement screening for new conditions – including recently in Kansas for Pompe and MPS I.
We express our deepest gratitude to the professionals in public health and medical labs during a tumultuous year with the raging pandemic. At Baebies, we are grateful to have multiple major milestones to celebrate as we reflect on 2020. See our annual Founder’s Report.
Baebies was selected as the winner of the AACC Disruptive Technology Award by a panel of expert judges at the #2020AACC Annual Meeting. During the virtual competition, Baebies presented FINDER®, a diagnostic platform featuring a toaster-sized instrument and disposable cartridge.
Digital microfluidics (DMF) technology is a method to programmably manipulate tiny droplets of liquid by electrical control of surface tension (or electrowetting) to perform tests on a disposable cartridge. Learn the unique benefits that DMF brings to diagnostic testing and newborn screening.
Extreme hyperbilirubinemia can cause bilirubin neurotoxicity. Infants with glucose-6-phosphate dehydrogenase (G6PD) deficiency can develop hemolysis and thus are at high risk. This peer-reviewed publication describes the evaluation of a device that quantitatively measures G6PD activity kinetically using digital microfluidics (DMF).
Baebies has been named a finalist for the 2020 American Association for Clinical Chemistry’s (AACC) Disruptive Technology Award for FINDER®, a near-patient testing platform. As a growth-stage company developing diagnostic products to provide a healthy start for children everywhere, Baebies FINDER tests for diseases from low blood volume (50 µL) with a turn-around time of approximately 15 minutes after sample introduction.
This peer-reviewed publication details the analytical validation, clinical validation, and implementation of a fluorometric assay for Mucopolysaccharidosis Type II (MPS II), also known as Hunter syndrome, at the Missouri State Public Health Laboratory, as published in the International Journal of Neonatal Screening (2020).
This peer-reviewed publication focuses on the development and practical experience of using digital microfluidic fluorometry (DMF) to screen newborns for MPS I in the USA, as published in the International Journal of Neonatal Screening (2020). Preliminary results of NBS for MPS II and MPS III using DMF are discussed.